Logo image of MYOV

Myovant Sciences Ltd (MYOV) Stock Fundamental Analysis

NYSE:MYOV - New York Stock Exchange, Inc. - BMG637AM1024 - Common Stock - Currency: USD

26.98  -0.01 (-0.04%)

After market: 26.98 0 (0%)

Fundamental Rating

2

Overall MYOV gets a fundamental rating of 2 out of 10. We evaluated MYOV against 571 industry peers in the Biotechnology industry. MYOV has a bad profitability rating. Also its financial health evaluation is rather negative. MYOV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MYOV has reported negative net income.
MYOV had a negative operating cash flow in the past year.
MYOV had negative earnings in each of the past 5 years.
In the past 5 years MYOV reported 4 times negative operating cash flow.
MYOV Yearly Net Income VS EBIT VS OCF VS FCFMYOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M

1.2 Ratios

MYOV has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYOV Yearly ROA, ROE, ROICMYOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

1.3 Margins

With an excellent Gross Margin value of 73.03%, MYOV belongs to the best of the industry, outperforming 84.43% of the companies in the same industry.
MYOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MYOV Yearly Profit, Operating, Gross MarginsMYOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

1

2. Health

2.1 Basic Checks

MYOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYOV has been increased compared to 1 year ago.
MYOV has a worse debt/assets ratio than last year.
MYOV Yearly Shares OutstandingMYOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
MYOV Yearly Total Debt VS Total AssetsMYOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

MYOV has an Altman-Z score of -2.98. This is a bad value and indicates that MYOV is not financially healthy and even has some risk of bankruptcy.
MYOV has a worse Altman-Z score (-2.98) than 60.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.98
ROIC/WACCN/A
WACC7.64%
MYOV Yearly LT Debt VS Equity VS FCFMYOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M -400M

2.3 Liquidity

A Current Ratio of 1.57 indicates that MYOV should not have too much problems paying its short term obligations.
With a Current ratio value of 1.57, MYOV is not doing good in the industry: 84.43% of the companies in the same industry are doing better.
MYOV has a Quick Ratio of 1.45. This is a normal value and indicates that MYOV is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.45, MYOV is not doing good in the industry: 83.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.45
MYOV Yearly Current Assets VS Current LiabilitesMYOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

MYOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.67%, which is quite impressive.
MYOV shows a strong growth in Revenue. In the last year, the Revenue has grown by 91.46%.
EPS 1Y (TTM)22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.24%
Revenue 1Y (TTM)91.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%84.11%

3.2 Future

Based on estimates for the next years, MYOV will show a very strong growth in Earnings Per Share. The EPS will grow by 25.08% on average per year.
Based on estimates for the next years, MYOV will show a very strong growth in Revenue. The Revenue will grow by 45.18% on average per year.
EPS Next Y19.42%
EPS Next 2Y25.59%
EPS Next 3Y20.67%
EPS Next 5Y25.08%
Revenue Next Year81.1%
Revenue Next 2Y53.4%
Revenue Next 3Y43.72%
Revenue Next 5Y45.18%

3.3 Evolution

MYOV Yearly Revenue VS EstimatesMYOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B
MYOV Yearly EPS VS EstimatesMYOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MYOV. In the last year negative earnings were reported.
Also next year MYOV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYOV Price Earnings VS Forward Price EarningsMYOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYOV Per share dataMYOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

MYOV's earnings are expected to grow with 20.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.59%
EPS Next 3Y20.67%

More info and screens

0

5. Dividend

5.1 Amount

MYOV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Myovant Sciences Ltd

NYSE:MYOV (3/9/2023, 8:04:00 PM)

After market: 26.98 0 (0%)

26.98

-0.01 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-26 2023-01-26/amc
Earnings (Next)05-08 2023-05-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners55.37%
Ins Owner Change0%
Market Cap2.62B
Analysts76
Price Target27.54 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.15%
Min EPS beat(2)-21.77%
Max EPS beat(2)5.48%
EPS beat(4)2
Avg EPS beat(4)1.97%
Min EPS beat(4)-21.77%
Max EPS beat(4)32.17%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.97%
Min Revenue beat(2)-4%
Max Revenue beat(2)9.95%
Revenue beat(4)2
Avg Revenue beat(4)4.58%
Min Revenue beat(4)-12.72%
Max Revenue beat(4)25.09%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.22%
EPS NY rev (3m)1.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.22%
Revenue NY rev (3m)1.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.78
OCFYN/A
SpS3.9
BVpS-5.74
TBVpS-5.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.03%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 65.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.45
Altman-Z -2.98
F-Score1
WACC7.64%
ROIC/WACCN/A
Cap/Depr(3y)67.93%
Cap/Depr(5y)160.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.24%
EPS Next Y19.42%
EPS Next 2Y25.59%
EPS Next 3Y20.67%
EPS Next 5Y25.08%
Revenue 1Y (TTM)91.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%84.11%
Revenue Next Year81.1%
Revenue Next 2Y53.4%
Revenue Next 3Y43.72%
Revenue Next 5Y45.18%
EBIT growth 1Y30.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.53%
EBIT Next 3Y15.08%
EBIT Next 5Y36.76%
FCF growth 1Y-161.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-160.74%
OCF growth 3YN/A
OCF growth 5YN/A